These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 15871765)

  • 1. Clinical management of oxaliplatin-associated neurotoxicity.
    Grothey A
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin-safety profile: neurotoxicity.
    Grothey A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):5-13. PubMed ID: 14523789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
    Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
    Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
    Argyriou AA; Velasco R; Briani C; Cavaletti G; Bruna J; Alberti P; Cacciavillani M; Lonardi S; Santos C; Cortinovis D; Cazzaniga M; Kalofonos HP
    Ann Oncol; 2012 Dec; 23(12):3116-3122. PubMed ID: 22865779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
    Kurniali PC; Luo LG; Weitberg AB
    Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Calcium Ameliorating Oxaliplatin-Induced Peripheral Neuropathy.
    Saif MW
    J Appl Res; 2004 Jan; 4(4):576-582. PubMed ID: 19816592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
    Lucchetta M; Lonardi S; Bergamo F; Alberti P; Velasco R; Argyriou AA; Briani C; Bruna J; Cazzaniga M; Cortinovis D; Cavaletti G; Kalofonos HP
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):899-902. PubMed ID: 23108696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
    Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
    Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
    Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
    Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin].
    Park S; Jung JJ; Kim GB; Yoon HS; Ko SH; Ko JE; Lee YS
    Korean J Gastroenterol; 2010 May; 55(5):340-3. PubMed ID: 20697195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
    Matsuda M; Matsusaka S; Kuboki Y; Itimura T; Ogura M; Suenaga M; Syouji D; Watanabe C; Chin K; Mizunuma N; Hatake K
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):461-6. PubMed ID: 18347395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
    Nakayama G; Kodera Y; Yokoyama H; Okuda N; Watanabe T; Tanaka C; Iwata N; Ohashi N; Koike M; Fujiwara M; Nakao A
    Int J Clin Oncol; 2011 Oct; 16(5):506-11. PubMed ID: 21431344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
    J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
    Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
    Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
    Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
    Chay WY; Tan SH; Lo YL; Ong SY; Ng HC; Gao F; Koo WH; Choo SP
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):270-7. PubMed ID: 21114776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity].
    Dong M; Xing PY; Liu P; Feng FY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2010 Mar; 32(3):208-11. PubMed ID: 20450590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.